Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 08 March 2012 | By Alexander Gaffney, RAC
Proposed legislation introduced in Congress on 7 March would encourage the US Food and Drug Administration (FDA) to seek and receive advice from experts in the field of rare diseases.
The Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012 (EXPERRT Act) would allow a consultation programs to be established for the purpose of allowing an exchange of expert information. The goal of the program is to allow FDA staff to better inform and strengthen the agency's ability to review therapies for rare diseases.
Experts may include:
The bill stipulates that the experts will likely be consulted to offer advice about rare diseases, the severity of rare diseases, unmet medical needs, clinical trials, and benefit:risk assessments.
House - H.R.4156 -- EXPERRT Act of 2012 (Introduced in House - IH)
Tags: Expert, therapies, orphan disease, rare disease, HR 4156, EXPERRT Act, Stearns, Markey, Latest News, Congress, rare